Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (1768)	9/29/2000 5:54:02 PM
From: greedsgd_2000	of 52153

Technically I believe you are correct....however the gist of the article I believe is summarized in paragraph 4 after mentioning a possible HIV vaccine when it says this "the study also encourages an approach to treatment research that until recently has gotten short shrift: fortifying the immune systems of patients infected with HIV, instead of merely trying to subdue the virus" This study only of course deals here with patients infected only within one month, hardly a practical approach (short of a vaccine) particularly in population groups that may have nearly nonexistent or little health services to begin with. HEPH is instead of course trying to fix what is broken (via the immune system), as opposed to merely limiting damage. In addition, the "proof of principal" referred to here is that "the human immune system can under certain circumstances control HIV infection" (A6 - top paragraph) Your point is well taken though, its a specialized approach here, not the same as what HEPH is running trials on currently.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next